Baxter (BAX) Financial Analysis & Valuation | Quarter Chart
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug recon... more
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $13.08B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Instruments & Supplies |
| Country | US | CEO | Andrew Hider |
| IPO Date | 1981-10-27 | CAGR | 3.99% |
| Employees | 37,500 | Website | www.baxter.com |
| Div. Yield | 7.17% | Payout Ratio | -17% |
| Buy Back Yield | — | Total Yield | 7.17% |
BAX chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $18.08B | P/E | 12.16 | Forward P/E | 12.4 | PEG | — |
| P/S | 0.13 | P/B | 0.22 | P/CF | 1.7 | P/FCF | 4.41 |
| Sales | $11.47B | Sales 1Y | 5.36% | Sales 3Y | -22.06% | Sales 5Y | -5.96% |
| EPS | $2.08 | EPS 1Y | 579.83% | EPS 3Y | -63.97% | EPS 5Y | -193.13% |
| Sales QoQ | 9.59% | EPS QoQ | -900% | Sales QoQ Avg | 1.55% | EPS QoQ Avg | 291.27% |
| Gross Margin | 30.08% | Operating Margin | -4.71% | Profit Margin | -9.27% | ROCE | -3.33% |
| ROA | -5% | ROE | -17% | Altman Z Score | 2.31 | Piotroski Score | 4 |
| Current Ratio | 1.95 | Quick Ratio | 1.32 | Cash Ratio | 0.6 | Op. CF Ratio | -0.06 |
| Debt/Equity | 1.56 | Debt/Assets | 0.49 | Lt Debt/Equity | 1.42 | Lt Debt/Cap. | 0.59 |
| Intrst Cov. | -2.02 | Inventory Turnover | 3.55 | Asset Turnover | 0.58 | Receivables Turnover | 6.18 |
| Enterprise Value | $18.08B | P/E Ratio | 12.16 |
| Forward P/E | 12.4 | PEG Ratio | — |
| P/S Ratio | 0.13 | P/B Ratio | 0.22 |
| P/CF Ratio | 1.7 | P/FCF Ratio | 4.41 |
| EPS | $2.08 | EPS Growth 1Y | 579.83% |
| EPS Growth 3Y | -63.97% | EPS Growth 5Y | -193.13% |
| Revenue Growth 1Y | 5.36% | Gross Margin | 30.08% |
| Operating Margin | -4.71% | Profit Margin | -9.27% |
| ROE | -17% | ROA | -5% |
| ROCE | -3.33% | Current Ratio | 1.95 |
| Quick Ratio | 1.32 | Cash Ratio | 0.6 |
| Debt/Equity | 1.56 | Interest Coverage | -2.02 |
| Altman Z Score | 2.31 | Piotroski Score | 4 |
Baxter (BAX) valuation & financials
Baxter (BAX) has a market capitalization of $13.08B and trades at a price-to-earnings ratio of 12.2. It operates in the Healthcare sector (Medical - Instruments & Supplies).
Baxter's revenue grew +5.4% over the last year.
Baxter's next earnings report is scheduled for October 29, 2026 before market open (provider scheduled date); analysts estimate EPS of $0.52. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)